The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | The role of belantamab mafodotin in myeloma treatment and managing the associated ocular toxicities
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, discusses the role of belantamab mafodotin in treating multiple myeloma (MM) and its associated toxicities. This agent has been shown to prolong progression-free survival (PFS), especially in patients at their first relapse. However, ocular toxicities can occur and should be managed with less frequent dosing. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
GSK: Consultancy, Honoraria, Research Funding; Janssen: Honoraria; BMS: Honoraria; AbbVie: Honoraria; Roche: Honoraria; University College London Hospitals NHS Foundation Trus: Current Employment. Gironella: Janssen: Consultancy, Honoraria; GSK: Consultancy.
